Active Biotech reports positive results from trial of Anyara

New York, June 5 - Active Biotech AB said results from its ongoing phase 1 study of Anyara for the treatment of advanced non-small cell lung, renal cell and pancreatic cancer indicated the treatment could be effective.

Researchers were able to generate reproducible induction of the immunostimulatory cytokine Interleukin-2, as a surrogate marker for T lymphocyte activation from Anyara injections. A correlation between IL-2 induction and prolonged survival for renal cancer patients had previously been shown with the first generation of Anyara.

In addition, a selective increase of Anyara-specific T lymphocytes following treatment was observed, which, the company said, shows that treatment selectively increases the amount of Anyara reactive T lymphocytes rather than just activatinig the patients' T lymphocytes in general.

The study is being performed at the Fox Chase Cancer Center in Philadelphia, the Radium Hospital in Oslo, Norway, and the Christie Hospital, in Manchester, U.K. Results were presented at the annual conference of the American Society for Clinical Oncology.

Active Biotech is a Stockholm, Sweden-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.